Compass Therapeutics, Inc. (CMPX)
| Market Cap | 367.38M +29.0% |
| Revenue (ttm) | n/a |
| Net Income | -68.17M |
| EPS | -0.40 |
| Shares Out | 180.09M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,144,370 |
| Open | 2.100 |
| Previous Close | 2.130 |
| Day's Range | 2.030 - 2.120 |
| 52-Week Range | 1.610 - 6.880 |
| Beta | 0.74 |
| Analysts | Strong Buy |
| Price Target | 8.82 (+332.35%) |
| Earnings Date | May 5, 2026 |
About CMPX
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company’s lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization. It also develops CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; C... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for CMPX stock is "Strong Buy." The 12-month stock price target is $8.82, which is an increase of 332.35% from the latest price.
News
Compass Therapeutics Transcript: Jefferies Global Healthcare Conference 2026
Lead oncology asset tovecimig demonstrated significant efficacy in biliary tract cancer, with plans for FDA submission and further studies underway. Promising early results from PD-1/PD-L1 bispecific and CD137 agonist programs, with multiple data updates expected later this year.
Compass Therapeutics to Participate in Upcoming June Investor Events
BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to t...
Compass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ASCO Annual Meeting
BOSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to t...
Compass Therapeutics Transcript: Stifel 2026 Targeted Oncology Virtual Forum
Significant PFS and ORR results for tovecimig support a planned BLA submission, with FDA feedback expected by Labor Day and confirmatory study designs under consideration. CTX-8371 data will debut at ASCO, and strong cash reserves support ongoing clinical and pipeline expansion.
Compass Therapeutics Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference
The company highlighted strong phase II/III data for its lead bispecific antibody in biliary tract cancer, with plans for FDA submission and significant commercial potential. Pipeline updates include promising early results for PD-1/PD-L1 and PD-1/VEGF bispecifics, and a new phase II study for a CD137 agonist.
Compass Therapeutics to Participate in Upcoming May Investor Events
BOSTON, May 12, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to t...
Compass Therapeutics reports Q1 EPS (10c), consensus (10c)
“We recently announced positive data from our Phase 2/3 study of tovecimig and look forward to meeting with the FDA before filing a BLA later this year. Most patients with…
Compass Therapeutics Reports 2026 First Quarter Financial Results and Provides Corporate Update
BOSTON, May 05, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to t...
Compass Therapeutics Earnings release: Q1 2026
Compass Therapeutics released its Q1 2026 earnings on May 5, 2026, summarizing the period's financial results.
Compass Therapeutics Quarterly report: Q1 2026
Compass Therapeutics has published its Q1 2026 quarterly earnings report on May 5, 2026.
Compass Therapeutics Proxy statement: Proxy filing
Compass Therapeutics filed a proxy statement on April 29, 2026, providing details for shareholder voting and corporate governance matters.
Compass Therapeutics Proxy statement: Proxy filing
Compass Therapeutics filed a proxy statement on April 29, 2026, providing details for shareholder voting and corporate governance matters.
Compass Therapeutics price target lowered to $7 from $13 at Canaccord
Canaccord lowered the firm’s price target on Compass Therapeutics (CMPX) to $7 from $13 and keeps a Buy rating on the shares. The firm said Tovecimig+paclitaxel clearly improves progression-free survi...
Compass Therapeutics downgraded to Market Perform from Outperform at Raymond James
Raymond James analyst Sean McCutcheon downgraded Compass Therapeutics (CMPX) to Market Perform from Outperform with no price target after Compass disclosed survival outcomes from COMPANION-002, the Ph...
Compass Therapeutics price target lowered to $6 from $12 at Stifel
Stifel lowered the firm’s price target on Compass Therapeutics (CMPX) to $6 from $12 and keeps a Buy rating on the shares. The firm believes event-driven COMPANION-002 secondary endpoint data…
Compass Therapeutics selloff ‘an over-reaction,’ says Jefferies
Jefferies believes the 63% selloff in Compass Therapeutics (CMPX) is “an over-reaction” given the totality of the company’s data and the biliary tract cancer market opportunity. The key focus is…
Leerink says Compass data supports path forward for tovecimig in 2L BTC
Leerink notes that Compass Therapeutics (CMPX) announced progression free survival and overall survival results for tovecimig in second line biliary tract cancer from the randomized COMPANION-002 stud...
Compass Therapeutics, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
SAN DIEGO, April 27, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Compass Therapeutics, Inc. (NASDAQ: CMPX). The investigation focuses on C...
H.C. Wainwright keeps Buy rating on Compass Therapeutics after data
After Compass Therapeutics (CMPX) announced key secondary endpoints findings, including progression free survival and overall survival, from its COMPANION-002 randomized Phase 2/3 study in patients wi...
Compass Therapeutics Transcript: Study update
The COMPANION-002 trial in advanced biliary tract cancer met its primary and key secondary endpoints, with tovecimig plus paclitaxel significantly improving response rate and progression-free survival over paclitaxel alone. Crossover patients showed notable survival benefit, and safety was manageable.
Compass Therapeutics Press release: Study update
Compass Therapeutics issued a press release on April 27, 2026, disclosing material business information to investors.
Compass Therapeutics Slides: Study update
Compass Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on April 27, 2026.
Compass Therapeutics reports additional COMPANION-002 study results
Compass Therapeutics (CMPX) announced that it met the secondary endpoint of PFS and showed additional results in the randomized COMPANION-002 study, which evaluated tovecimig plus paclitaxel versus pa...
Tovecimig Demonstrates Statistically Significant Benefit in COMPANION-002 Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer
Tovecimig (a DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel demonstrated a highly statistically significant improvement versus paclitaxel alone in the key secondary endpoint of medi...
Compass Therapeutics to Announce Topline Secondary Endpoints from the Phase 2/3 COMPANION-002 Study of Tovecimig in Patients with Biliary Tract Cancer
BOSTON, April 24, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to...